Drug Profile
CCP 110
Alternative Names: CCP-110Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Castle Creek Pharmaceuticals
- Class
- Mechanism of Action Ammonia scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperammonaemia
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for phase-I development in Hyperammonaemia in Unknown
- 12 Oct 2017 Phase-I clinical trials in Hyperammonaemia before October 2017 (Castle Creek Pharmaceuticals pipeline, October 2017)